Rx (Prescription Medicine)
USD $ 15.00
Bortesam 2mg 注射液，含有硼替佐米，通过抑制癌细胞生长，用于治疗多发性骨髓瘤和套细胞淋巴瘤。本品需由医疗专业人员按处方进行注射给药。
Bortesam 2mg 注射液是一种重要的药物，其活性成分为硼替佐米。它主要用于治疗多发性骨髓瘤（一种血癌）和套细胞淋巴瘤（另一种影响淋巴系统的癌症）。硼替佐米通过抑制蛋白酶体发挥作用，蛋白酶体对细胞生长和存活至关重要，从而减缓或阻止癌细胞的增殖。
本药物通过注射给药，通常由医疗专业人员操作。严格遵循处方剂量和给药方案至关重要。患者应告知医生任何既往病史，特别是心脏问题、肺部疾病或神经问题，以及正在服用的任何其他药物。常见的副作用可能包括疲劳、腹泻、便秘、恶心和周围神经病变。患者应立即向医生报告任何严重或持续的副作用。
Bortesam 2mg 注射液应在室温下储存，避光防潮，并置于儿童无法触及的地方。务必在合格医疗服务提供者的指导下处理和使用本药物。
| Molecule | |
|---|---|
| Strength | |
| Pack Quantity | |
| Medicine Form | |
| Medicine Type | |
| Rx Status | |
| Country Of Origin | |
| Packaging Type | |
| Brand Name |
其他品牌的 Bortezomib 2 mg — 同一活性成分且强度相同，但来自不同制造商。
医学审核
Renu Meena, B.Pharm
Medical Content Writer
Renu Meena is an experienced Medical Content Writer with a strong foundation in pharmacy practice. She holds a Bachelor of Pharmacy (B.Pharm) degree from Rajasthan University of Health Sciences (RUHS), Jaipur, and is registered with the Rajasthan State Pharmacy Council (Reg. No. 55661). With 4+ years of experience across clinical pharmacy and medical content development, she creates evidence-based content for medicines, diseases, and patient education. Her work is shaped by a strong understanding of pharmacovigilance and regulatory standards, including ICH guidelines, GVP modules, ICD-10/11, and safety reporting requirements. Renu focuses on making complex medical information simple, accurate, and useful for readers while maintaining high quality and compliance.
